Logo image of OCS

OCULIS HOLDING AG (OCS) Stock Fundamental Analysis

USA - NASDAQ:OCS - CH1242303498 - Common Stock

21.2 USD
-0.62 (-2.84%)
Last: 10/22/2025, 8:00:02 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to OCS. OCS was compared to 191 industry peers in the Pharmaceuticals industry. OCS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. OCS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OCS has reported negative net income.
OCS had a negative operating cash flow in the past year.
OCS had negative earnings in each of the past 5 years.
In the past 5 years OCS always reported negative operating cash flow.
OCS Yearly Net Income VS EBIT VS OCF VS FCFOCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

OCS has a Return On Assets of -59.15%. This is in the lower half of the industry: OCS underperforms 64.40% of its industry peers.
OCS has a Return On Equity (-75.08%) which is in line with its industry peers.
Industry RankSector Rank
ROA -59.15%
ROE -75.08%
ROIC N/A
ROA(3y)-84.45%
ROA(5y)-75.22%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OCS Yearly ROA, ROE, ROICOCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OCS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OCS Yearly Profit, Operating, Gross MarginsOCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

OCS has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, OCS has a worse debt to assets ratio.
OCS Yearly Shares OutstandingOCS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
OCS Yearly Total Debt VS Total AssetsOCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

OCS has an Altman-Z score of 14.35. This indicates that OCS is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of OCS (14.35) is better than 87.43% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that OCS is not too dependend on debt financing.
OCS's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. OCS outperforms 59.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 14.35
ROIC/WACCN/A
WACCN/A
OCS Yearly LT Debt VS Equity VS FCFOCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 4.55 indicates that OCS has no problem at all paying its short term obligations.
OCS's Current ratio of 4.55 is fine compared to the rest of the industry. OCS outperforms 66.49% of its industry peers.
A Quick Ratio of 4.55 indicates that OCS has no problem at all paying its short term obligations.
With a decent Quick ratio value of 4.55, OCS is doing good in the industry, outperforming 67.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.55
Quick Ratio 4.55
OCS Yearly Current Assets VS Current LiabilitesOCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

OCS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -31.64%.
EPS 1Y (TTM)-31.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%6.53%

3.2 Future

OCS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.73% yearly.
Based on estimates for the next years, OCS will show a very strong growth in Revenue. The Revenue will grow by 219.10% on average per year.
EPS Next Y9.88%
EPS Next 2Y0.44%
EPS Next 3Y-2.62%
EPS Next 5Y16.73%
Revenue Next Year-1.68%
Revenue Next 2Y265.88%
Revenue Next 3Y310.12%
Revenue Next 5Y219.1%

3.3 Evolution

OCS Yearly Revenue VS EstimatesOCS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
OCS Yearly EPS VS EstimatesOCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OCS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OCS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCS Price Earnings VS Forward Price EarningsOCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCS Per share dataOCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

OCS's earnings are expected to decrease with -2.62% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.44%
EPS Next 3Y-2.62%

More info and screens

0

5. Dividend

5.1 Amount

OCS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OCULIS HOLDING AG

NASDAQ:OCS (10/22/2025, 8:00:02 PM)

21.2

-0.62 (-2.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-21 2025-08-21/amc
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners31.34%
Inst Owner ChangeN/A
Ins Owners3.04%
Ins Owner ChangeN/A
Market Cap1.11B
Revenue(TTM)N/A
Net Income(TTM)-107433000
Analysts89.09
Price Target37.4 (76.42%)
Short Float %0.02%
Short Ratio0.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-30.35%
Min EPS beat(2)-56.2%
Max EPS beat(2)-4.51%
EPS beat(4)1
Avg EPS beat(4)-27.81%
Min EPS beat(4)-56.2%
Max EPS beat(4)1.26%
EPS beat(8)2
Avg EPS beat(8)-22.45%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)32.75%
Min Revenue beat(2)28.68%
Max Revenue beat(2)36.82%
Revenue beat(4)2
Avg Revenue beat(4)-10.95%
Min Revenue beat(4)-98.55%
Max Revenue beat(4)36.82%
Revenue beat(8)3
Avg Revenue beat(8)3.92%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.05%
EPS NQ rev (1m)2.96%
EPS NQ rev (3m)12.13%
EPS NY rev (1m)4.43%
EPS NY rev (3m)3.33%
Revenue NQ rev (1m)-16.67%
Revenue NQ rev (3m)6.32%
Revenue NY rev (1m)0%
Revenue NY rev (3m)24.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.18
P/tB 6.81
EV/EBITDA N/A
EPS(TTM)-2.93
EYN/A
EPS(NY)-2.61
Fwd EYN/A
FCF(TTM)-1.4
FCFYN/A
OCF(TTM)-1.37
OCFYN/A
SpS0
BVpS3.43
TBVpS3.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -59.15%
ROE -75.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-84.45%
ROA(5y)-75.22%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 299.38%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.55
Quick Ratio 4.55
Altman-Z 14.35
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)418.9%
Cap/Depr(5y)255.58%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.92%
EPS Next Y9.88%
EPS Next 2Y0.44%
EPS Next 3Y-2.62%
EPS Next 5Y16.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%6.53%
Revenue Next Year-1.68%
Revenue Next 2Y265.88%
Revenue Next 3Y310.12%
Revenue Next 5Y219.1%
EBIT growth 1Y-20.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.09%
EBIT Next 3Y-25.3%
EBIT Next 5Y12%
FCF growth 1Y11.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.79%
OCF growth 3YN/A
OCF growth 5YN/A